Investigating the effect of the oral microbiome on cognition in HIV-infected chronic cannabis users

Date Added
February 9th, 2023
PRO Number
Pro00117243
Researcher
Wei Jiang

List of Studies


Keywords
Brain, Dental, HIV / AIDS, Memory Loss, Mental Health, Nervous System, Psychiatry, Substance Use
Summary

This study will examine how marijuana use can affect oral bacteria and brain health in people with HIV and without HIV. Early studies show that marijuana users have more oral bacteria than non-marijuana users. The increase in bacteria is believed to affect brain health. Participation in the study will be one visit. The visit will take approximately 120 minutes.

Institution
MUSC
Recruitment Contact
Wei Jiang
843-876-2457
jianw@musc.edu

PCORI 1: Improving Maternal Mental Health & Substance Use Disorder Screening and Treatment

Date Added
November 1st, 2022
PRO Number
Pro00123833
Researcher
Constance Guille

List of Studies


Keywords
Depression, Mental Health, Obstetrics and Gynecology, Post Partum Depression, Pregnancy, Psychiatry, Substance Use, Women's Health
Summary

The purpose of the study is to compare a text message based mental health and substance use screening and referral to treatment program, called Listening to Women and Pregnant and Postpartum People (LTWP), to standard of care in-person mental health and substance use screening to look at rates of treatment attendance and retention in treatment. Participation would involve completing online surveys. You may be eligible to participate if you are age 18-45 years, are pregnant and entering prenatal care in one of MUSC's OB clinics, and attended a prenatal appointment at an MUSC clinic.

Institution
MUSC
Recruitment Contact
Edie Douglas
843-792-5958
douglaed@musc.edu

PCORI 1: Improving Maternal Mental Health & Substance Use Disorder Screening and Treatment

Date Added
November 1st, 2022
PRO Number
Pro00123833
Researcher
Constance Guille

List of Studies


Keywords
Depression, Mental Health, Obstetrics and Gynecology, Post Partum Depression, Pregnancy, Psychiatry, Substance Use, Women's Health
Summary

The purpose of the study is to compare a text message based mental health and substance use screening and referral to treatment program, called Listening to Women and Pregnant and Postpartum People (LTWP), to standard of care in-person mental health and substance use screening to look at rates of treatment attendance and retention in treatment. Participation would involve completing online surveys. You may be eligible to participate if you are age 18-45 years, are pregnant and entering prenatal care in one of MUSC's OB clinics, and attended a prenatal appointment at an MUSC clinic.

Institution
MUSC Health Florence Medical Center
Recruitment Contact
Edie Douglas
843-792-5958
douglaed@musc.edu

PCORI 1: Improving Maternal Mental Health & Substance Use Disorder Screening and Treatment

Date Added
November 1st, 2022
PRO Number
Pro00123833
Researcher
Constance Guille

List of Studies


Keywords
Depression, Mental Health, Obstetrics and Gynecology, Post Partum Depression, Pregnancy, Psychiatry, Substance Use, Women's Health
Summary

The purpose of the study is to compare a text message based mental health and substance use screening and referral to treatment program, called Listening to Women and Pregnant and Postpartum People (LTWP), to standard of care in-person mental health and substance use screening to look at rates of treatment attendance and retention in treatment. Participation would involve completing online surveys. You may be eligible to participate if you are age 18-45 years, are pregnant and entering prenatal care in one of MUSC's OB clinics, and attended a prenatal appointment at an MUSC clinic.

Institution
MUSC Health Lancaster Medical Center
Recruitment Contact
Edie Douglas
843-792-5958
douglaed@musc.edu

Managing Inpatient Neuropsychiatric Conditions Using Wearable Auricular Vagus Stimulation: The iWAVE Pilot Trial

Date Added
June 7th, 2022
PRO Number
Pro00120876
Researcher
Bashar Badran

List of Studies


Keywords
Anxiety, Psychiatry
Summary

This is a research study to find out if mental health symptoms in patients admitted to the Institute of Psychiatry are affected by a form of ear stimulation called transcutaneous auricular vagus nerve stimulation, or taVNS. Participants will receive ear stimulation during their inpatient treatment at the Institute of Psychiatry. Participants will be randomly assigned to either receive ear stimulation for 1 day (up to 9 treatments over the course of a single day) or 3 days (up to 3 treatments per day), and will have a 50:50 chance of being in either group (like the flip of a coin). Each treatment will last up to 30 minutes and there will be a break of at least 30 minutes in between treatments. The study team will ask participants to complete a group of questionnaires at the beginning and end of the study. In addition, there are several questionnaires that will be completed daily while participants are receiving ear stimulation. Participants in the 1 day stimulation group will also receive 2 days of follow up questionnaires after the initial day of stimulation. The questionnaires will ask questions about mental health symptoms that subjects may or may not be experiencing, including questions about mood, anxiety, and sleep. The ear stimulation treatments will not interfere with the care subjects are receiving from the medical team. In order to qualify for this study, participants must be actively receiving inpatient care at the MUSC Institute of Psychiatry.

Institution
MUSC
Recruitment Contact
Dillon Connolly
843-792-9502
connolld@musc.edu

Neurobehavioral Effects of Cannabidiol in Youth Alcohol Use Disorder

Date Added
May 3rd, 2022
PRO Number
Pro00119770
Researcher
Lindsay Squeglia

List of Studies


Keywords
Adolescents, Alcohol, Brain, Drug Studies, Pediatrics, Psychiatry, Substance Use
Summary

This study is testing cannabidiol (CBD) as a possible medication to treat alcohol use disorder. Youth (ages 16-22) will receive one dose of CBD (600mg) or placebo (i.e., sugar water) before two different MRI sessions (separated by 2 weeks) to see how CBD affects the brain. The full study will last approximately one month.

Participants must provide informed consent and youth under 18 must have parental consent to participate.

Compensation is available to those who qualify.

Institution
MUSC
Recruitment Contact
Cori Herring
843-792-8207
herrinco@musc.edu

Gabapentin for Restoring GABA/glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders: A Randomized, Double-blind, Placebo-controlled, Parallel-group, MRI Study

Date Added
August 3rd, 2021
PRO Number
Pro00112593
Researcher
James Prisciandaro

List of Studies


Keywords
Depression, Mental Health, Psychiatry, Substance Use
Summary

This research study evaluates the effects of anFDA-approved medication Gabapentin in individuals with Bipolar Disorder who smoke marijuana. Participants in the study will will be assigned to take either Gabapentin or a matched placebo. Study medication will be taken for 17 days. There will be 5 study visits, with 2 MRI brain imaging scans completed. Questionnaires and clinical interview measures will be completed at study visits along with consistent assessment of potential side effects from study medication.

Institution
MUSC
Recruitment Contact
Sara Hix
843-792-0572
hixs@musc.edu

Gender and Sex Hormone Influences on Cannabis Use Disorder Remission

Date Added
June 1st, 2021
PRO Number
Pro00110801
Researcher
Rachel Tomko

List of Studies


Keywords
Hormones, Mental Health, Psychiatry, Substance Use
Summary

Adults (ages 18+) who would like to reduce their cannabis use (N=224) will be enrolled in an 8-week treatment program. All participants will receive counseling (1 goals session with a therapist followed by 7 weekly computerized cognitive-behavioral therapy sessions). Detailed cannabis assessments (biological and self-report) will be conducted throughout treatment and at 1-, 2-, and 3-months post-treatment completion. Daily electronic diaries will be administered via text message to record detailed logs of cannabis use quantity and frequency. Salivary samples will be collected (and video observed) daily throughout treatment to analyze for progesterone.

Institution
MUSC
Recruitment Contact
Kevin Branson
843-792-9257
bransonk@musc.edu

rTMS for Stimulant Use Disorders

Date Added
March 2nd, 2021
PRO Number
Pro00107688
Researcher
Kathleen Brady

List of Studies


Keywords
Brain, Mental Health, Psychiatry, Substance Use
Summary

The study will compare Repetitive Transcranial Magnetic Stimulation (rTMS) with placebo rTMS in reducing Cocaine and/or Methamphetamine use. Study participants will be adults who currently use Cocaine and/or Methamphetamine. Eligible participants will receive multiple sessions of repetitive Transcranial Magnetic Stimulation (rTMS) or placebo rTMS over the course of an 8-week treatment period and will complete follow-up assessments for 8 weeks post-treatment. Participants will be compensated for participating.

Institution
MUSC
Recruitment Contact
Alexandra Herron
843-214-4496
herronal@musc.edu

Oxytocin to Enhance Integrated Exposure-Based Treatment of Co-occurring Alcohol Use Disorder and PTSD

Date Added
November 3rd, 2020
PRO Number
Pro00103198
Researcher
Sudie Back

List of Studies


Keywords
Alcohol, Mental Health, Military, Psychiatry, Stress Disorders
Summary

The purpose(s) of the research is to test a new medication in combination with a talk therapy for Veterans experiencing posttraumatic stress disorder (PTSD) and who may have alcohol use disorder (AUD). The study consists of 12 weekly therapy sessions. Once per week before each therapy session, an intranasal dose of investigational medication will be administered. The study also involves 3 and 6-month follow-up appointments and the administration of questionnaires at each visit.

Institution
MUSC
Recruitment Contact
Stacey Sellers
843-792-5807
sellersst@musc.edu



-- OR --